Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan Province, China; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, China.
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, Henan Province, China.
Eur J Med Chem. 2024 May 5;271:116449. doi: 10.1016/j.ejmech.2024.116449. Epub 2024 Apr 26.
Methicillin-resistant Staphylococcus aureus (MRSA) is a widespread pathogen causing clinical infections and is multi-resistant to many antibiotics, making it urgent need to develop novel antibacterials to combat MRSA. Herein, we designed and prepared a series of novel osthole amphiphiles 6a-6ad by mimicking the structures and function of antimicrobial peptides (AMPs). Antibacterial assays showed that osthole amphiphile 6aa strongly inhibited S. aureus and 10 clinical MRSA isolates with MIC values of 1-2 μg/mL, comparable to that of the commercial antibiotic vancomycin. Additionally, 6aa had the advantages of rapid bacteria killing without readily developing drug resistance, low toxicity, good membrane selectivity, and good plasma stability. Mechanistic studies indicated that 6aa possesses good membrane-targeting ability to bind to phosphatidylglycerol (PG) on the bacterial cell membranes, thereby disrupting the cell membranes and causing an increase in intracellular ROS as well as leakage of proteins and DNA, and accelerating bacterial death. Notably, in vivo activity results revealed that 6aa exhibits strong anti-MRSA efficacy than vancomycin as well as a substantial reduction in MRSA-induced proinflammatory cytokines, including TNF-α and IL-6. Given the impressive in vitro and in vivo anti-MRSA efficacy of 6aa, which makes it a potential candidate against MRSA infections.
耐甲氧西林金黄色葡萄球菌(MRSA)是一种广泛存在的病原体,可引起临床感染,并且对许多抗生素具有多重耐药性,因此迫切需要开发新型抗菌药物来对抗 MRSA。在此,我们通过模拟抗菌肽(AMP)的结构和功能,设计并制备了一系列新型蛇床子素两亲体 6a-6ad。抗菌测定表明,蛇床子素两亲体 6aa 强烈抑制金黄色葡萄球菌和 10 株临床分离的 MRSA,MIC 值为 1-2μg/mL,与商业抗生素万古霉素相当。此外,6aa 具有快速杀菌、不易产生耐药性、低毒性、良好的膜选择性和良好的血浆稳定性等优点。机制研究表明,6aa 具有良好的膜靶向能力,可与细菌细胞膜上的磷脂酰甘油(PG)结合,从而破坏细胞膜并导致细胞内 ROS 增加以及蛋白质和 DNA 的渗漏,加速细菌死亡。值得注意的是,体内活性结果表明,6aa 对 MRSA 的疗效强于万古霉素,并且可显著降低 MRSA 诱导的促炎细胞因子,如 TNF-α 和 IL-6。鉴于 6aa 令人印象深刻的体外和体内抗 MRSA 疗效,它可能成为对抗 MRSA 感染的潜在候选药物。